Clinical Trial

A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)

Study acronym: REGISTEM
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 7, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a prospective, multicenter non-interventional cohort study designed to develop a registry in unresectable locally advanced or metastatic disease.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2016-06-27; most recent amendment 2026-04-01.
Status change: Not Yet Recruiting → Recruiting 2017-06-07
Trial Details
NCT Number NCT02819882
Lead Sponsor Spanish Breast Cancer Research Group
Collaborators: Hoffmann-La Roche, Novartis, AstraZeneca, Pfizer, Celgene
Conditions Breast Neoplasms
Enrollment 1,867 participants
Start Date 2016-08
Primary Completion 2026-06 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2026-04-07